Knight Therapeutics Expands TAVALISSE® Footprint in Latin America with Mexico Launch
Event summary
- Knight Therapeutics launched TAVALISSE® (fostamatinib) in Mexico for chronic immune thrombocytopenia (ITP) treatment, following regulatory approval in 2024.
- The launch follows a 2022 agreement with Rigel Pharmaceuticals for exclusive Latin American commercialization rights.
- TAVALISSE® is the first SYK inhibitor approved in Mexico for ITP, offering a novel mechanism of action for treatment-resistant patients.
- Knight expects to launch TAVALISSE® in Brazil in the second half of 2026 after recent regulatory approval.
The big picture
Knight Therapeutics' Mexico launch of TAVALISSE® underscores its strategy of expanding access to innovative therapies in underserved Latin American markets. The move aligns with broader industry trends of regional pharmaceutical companies leveraging exclusive licensing agreements to strengthen their portfolios. With chronic ITP representing a significant unmet medical need, Knight's ability to execute on its regulatory and commercial milestones will be key to sustaining growth in the region.
What we're watching
- Regulatory Progress
- The pace at which Knight secures approvals in Colombia, Argentina, and Paraguay will determine the speed of regional expansion.
- Commercial Execution
- Whether Knight can effectively penetrate the Mexican market and replicate success in Brazil will be critical for revenue growth.
- Competitive Dynamics
- How existing ITP therapies in Mexico respond to TAVALISSE®'s introduction could impact market adoption and pricing power.
Related topics